Nasdaq nmra.

Progressing NMRA-511 and NMRA-266 toward near-term clinical milestones and advancing multiple preclinical neuropsychiatric and neurodegeneration programs. ... Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception ...Neumora Therapeutics, Inc. (NASDAQ: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the pricing of its initial public offering of ...VinFast Auto Ltd. (NASDAQ:VFS) gained 13.6% to $12.73 following a report suggesting the company is planning to set up a manufacturing plant in India. Neumora Therapeutics, Inc. (NASDAQ:NMRA ...Nov 27, 2023 · NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders.

Sep 21, 2023 · Shares of Neumora Therapeutics (NASDAQ: NMRA) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. NASDAQ: NMRA · IEX Real-Time Price · USD. Add to Watchlist 11.92 +0.01 (0.08%) Nov 24, 2023, 4:30 PM EST - Market closed. Overview; Financials; ... Stock Price Forecast. According to 5 stock analysts, the average 12-month stock price forecast for NMRA stock stock is $22, which predicts an increase of 84.56%. The lowest target is $18 …

The Watertown, MA-based Neumora Therapeutics (NASDAQ:NMRA), a Phase 3 biotech developing therapies for brain diseases has priced its initial public offering of 14.71 million shares of its common ...

The latest price target for Neumora Therapeutics (NASDAQ: NMRA) was reported by JP Morgan on Wednesday, November 8, 2023. The analyst firm set a price target ...WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience …WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the third quarter ended September 30, 2023 and provided a general business update.WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience …15 Sep 2023 ... ... Nasdaq under the NMRA ticker, which could give it a market valuation of $2.74 billion if fully exercised. It is also due to make its debut ...

View NMRA historial stock data and compare to other stocks and exchanges. ... Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.

CGC. Canopy Growth Corporation Common Shares. $1.275 -0.065 -4.85%. Find the latest SEC Filings data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.

Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.2 hari yang lalu ... Read William Blair Brokers Cut Earnings Estimates for Neumora Therapeutics, Inc. (NASDAQ:NMRA) at Techdows.Neumora Therapeutics, Inc. Common Stock (NMRA) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest for ...Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep experience implementing successful clinical programs to support the development of novel medicines. WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company …

Neumora Therapeutics is a biotech company located in Massachusetts, United States, which is part of the Healthcare sector, and is traded under the ticker NMRA on the NASDAQ exchange. Neumora Therapeutics stock last closed at $11.69 , down 1.35% from the previous day, and has decreased N/A in one year.Navacaprant is an investigational once-daily oral medication that is designed to modulate the dopamine and reward processing pathways. Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR).Nov 29, 2023 · markets.businessinsider.com - November 27 at 10:19 AM. Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study. finance.yahoo.com - November 27 at 10:19 AM. Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Up to $11.69. americanbankingnews.com - November 24 at 5:19 AM. When is Neumora Therapeutics (NASDAQ:NMRA) reporting earnings? A. Neumora Therapeutics ( NMRA) is scheduled to report earnings on February 15, 2024. The last reported earnings were for reported on ...Neumora Therapeutics (NASDAQ: NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with ...Atomera Inc (NASDAQ:ATOM)’s traded shares stood at 0.16 million during the last session, with the company’s beta value hitting 1.45. At the close of trading, the stock’s price was $6.97, to imply an increase of 0.29% or $0.02 in intraday trading. The ATOM share’s 52-week high remains $10.72 ...

A. The latest price target for Tilray Brands ( NASDAQ: TLRY) was reported by Roth MKM on Friday, September 1, 2023. The analyst firm set a price target for 2.50 expecting TLRY to rise to within 12 ...

Sep 29, 2023 · Neumora Therapeutics (NASDAQ: NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with ... Neumora Therapeutics Inc. (NASDAQ:NMRA)’s traded shares stood at 0.14 million during the last session. At the close of trading, the stock’s price was $11.91, to imply an increase of 1.88% or $0.22 in intraday trading. The NMRA share’s 52-week high remains $17.74, putting it -48.95% down since ...Progressing NMRA-511 and NMRA-266 toward near-term clinical milestones and advancing multiple preclinical neuropsychiatric and neurodegeneration programs. ... Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception ...EHang Holdings Ltd ADR (NASDAQ:EH) showed a performance of -24.51% in past 30-days. Number of shares sold short was 8.79 million shares which calculate 11.8 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $222.79 to the stock, which implies a rise of 93.55% to its current value.NMRA Neumora Therapeutics Inc Form 8-K - Current report false 0001885522 0001885522 2023-11-01 2023-11-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT R...WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the third quarter ended September 30, 2023 and provided ... (NMRA-140) is a highly selective, novel, …Sep 12, 2023 · A Quick Take On Neumora Therapeutics. Neumora Therapeutics, Inc. ( NASDAQ: NMRA) has filed proposed terms to raise $250 million from the sale of its common stock in an IPO, according to an amended ... Ventyx Biosciences, Inc. (NASDAQ:VTYX) fell 22.1% to $23.38 after the company announced results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis.

Neumora Therapeutics (NASDAQ: NMRA) · Neumora Therapeutics Return vs. S&P · Neumora Therapeutics Company Info · News & Analysis · Financial Health · Valuation.

The Watertown, MA-based Neumora Therapeutics (NASDAQ:NMRA), a Phase 3 biotech developing therapies for brain diseases has priced its initial public offering of 14.71 million shares of its common ...

VinFast Auto Ltd. (NASDAQ:VFS) gained 13.6% to $12.73 following a report suggesting the company is planning to set up a manufacturing plant in India. Neumora Therapeutics, Inc. (NASDAQ:NMRA ...Nov 9, 2023 · Neumora Therapeutics, Inc. ( NASDAQ:NMRA – Get Free Report) Director Kristina Burow bought 43,082 shares of the business’s stock in a transaction dated Monday, November 6th. The stock was ... VinFast Auto Ltd. (NASDAQ:VFS) gained 13.6% to $12.73 following a report suggesting the company is planning to set up a manufacturing plant in India. Neumora Therapeutics, Inc. (NASDAQ:NMRA ...Sep 28, 2023 · VinFast Auto Ltd. (NASDAQ:VFS) gained 13.6% to $12.73 following a report suggesting the company is planning to set up a manufacturing plant in India. Neumora Therapeutics, Inc. (NASDAQ:NMRA ... Investors can buy NMRA even cheaper than Gosebruch did, with shares changing hands as low as $10.01 at last check today -- that's 20.7% under Gosebruch's purchase price. VIDEO: Thursday 9/21 ...Neumora Therapeutics, Inc. Common Stock (NMRA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Sep 21, 2023 · Shares of Neumora Therapeutics (NASDAQ: NMRA) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. “The ...ImmunityBio (NASDAQ:IBRX) and Neumora Therapeutics (NASDAQ:NMRA) are both medical companies, but which is the superior stock?We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and …1.55. EBIT. -130.9. -237.31. Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual ( 10-K) and quarterly ( 10-Q) reports submitted to the Securities and Exchange Commission (SEC). Detailed annual and quarterly income statement for Neumora Therapeutics, Inc. (NMRA). See many years of revenue, expenses and ...

Neumora Therapeutics, Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics, Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Ventyx Biosciences, Inc. (NASDAQ:VTYX) fell 22.1% to $23.38 after the company announced results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis.Stock analysis for Neumora Therapeutics Inc (NMRA:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Quais ferramentas de análise técnica podem ser usadas para analisar Neumora Therapeutics, Inc.? Confira vários osciladores, médias móveis e outros indicadores …Instagram:https://instagram. brrnbest algorithmic tradingdaytrade simulatorotcmkts exrof WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the third quarter ended September 30, 2023 and provided ... (NMRA-140) is a highly selective, novel, …Based on analysts offering 12 month price targets for NMRA in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . cheap motorcycle insurance azvanguard emerging market About Robert Lenz, M.D., Ph.D., executive vice president, head of research and development Dr. Rob Lenz is executive vice president, head of research and development at Neumora.Neumora Therapeutics (NASDAQ:NMRA) shares are up over 15% this morning. 10 Top Losers Vivos Therapeutics (NASDAQ: VVOS ) stock is plummeting nearly 34% after a massive rally yesterday on FDA news . state farm umbrella insurance review On October 10, 2023, Geoff Meacham, an analyst at Bank of America Securities, commenced coverage on Neumora Therapeutics (NASDAQ:NMRA) by Analyst Coverage and Price Targets for Neumora Therapeutics - Best StocksNeumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.About Robert Lenz, M.D., Ph.D., executive vice president, head of research and development Dr. Rob Lenz is executive vice president, head of research and development at Neumora.